TOP2A index predicts response to anthracycline containing chemotherapy. A) Experimental strategy to identify the TOP2A index. B) TOP2A co-expressed probesets within the three discovery cohorts. C) Experimental strategy to validate the TOP2A index. D) ROC Analysis of TOP2A index scores and response to T/FAC neoadjuvant chemotherapy (AUC: 0.73, p < 0.0001). E) TOP2A index scores of patients who experienced pCR or had RD after neoadjuvant chemotherapy ( p < 0.0001, t-test).
Hallett et al. BMC Medical Genomics 2012 5:16 doi:10.1186/1755-8794-5-16